(Reuters) – Novavax Inc said on Thursday its vaccine to prevent RSV infection, a leading cause of a respiratory disease in infants, failed to meet the main goal of a late stage study.
The vaccine failed to prevent lower respiratory tract infection related to RSV, or respiratory syncytial virus, the company said.
Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar
Our Standards:The Thomson Reuters Trust Principles.
Source: Reuters.com
